Komori
PhoenixBio (6190) · RiskRestated

Recovery of Upfront Research and Development and Capital Investment Costs

First written in FY2017. 5 of 6 entries say "Restated". Latest entry: FY2023.

6entries
7years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2017 – FY20232017: 120172018: 120182019: 120192020: 120202021: 120212022: 020222023: 12023
Same theme, other companies
Non-recovery and Impairment of Research and Development Expenditure and Capital InvestmentA theme 52 companies write about · 54 as a headwind · 0 as a tailwind

The whole theme swung hardest in 2026: 19 of 24 companies on the "Worse" side.

11 other companies' latest entry also says "Restated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 52 companies compared. The sentences above are computed from all 52.
Full recordFilings, disclosures and news, newest first
  1. FY2023RestatedAnnual report

    「Research and development expenses account for a significant proportion of the expenses of our group, and we conduct research and development and capital investment ahead of time with a view to the future. However, if research and development does not produce the expected results, we may be unable to recover the research and development expenses and capital investment costs incurred in advance.」

    The possibility that research and development and capital investment conducted ahead of time may fail to produce the expected results and the investments may not be recovered continues to be disclosed.
  2. FY2021RestatedAnnual report

    「However, there is no guarantee that these investments will immediately generate revenue, and consequently they may not lead to the expected profits.」

    While investing funds raised through convertible bonds with stock acquisition rights and other instruments in expanded uses, consortia, CRO partnerships, production facilities and other areas, the disclosure expressly states the risk that the investments may not be recovered or converted into profits.
  3. FY2020RestatedAnnual report

    「Research and development expenses account for a significant proportion of the expenses of our group, and we conduct research and development and capital investment ahead of time with a view to the future. However, if research and development does not produce the expected results, we may be unable to recover the research and development expenses and capital investment costs incurred in advance.」

    The possibility that research and development and capital investment conducted ahead of time may fail to produce the expected results and the investments may not be recovered continues to be disclosed.
  4. FY2019RestatedAnnual report

    「Research and development expenses account for a significant proportion of the expenses of our group, and we conduct research and development and capital investment ahead of time with a view to the future. However, if research and development does not produce the expected results, we may be unable to recover the research and development expenses and capital investment costs incurred in advance.」

    While conducting research and development and capital investment ahead of time, the possibility that the expected results may not be achieved and the investments may not be recovered continues to be disclosed.
  5. FY2018RestatedAnnual report

    「Research and development expenses account for a significant proportion of the expenses of our group, and we conduct research and development and capital investment ahead of time with a view to the future. However, if research and development does not produce the expected results, we may be unable to recover the research and development expenses and capital investment costs incurred in advance.」

    While conducting research and development and capital investment ahead of time, the possibility that the expected results may not be achieved and the investments may not be recovered continues to be disclosed.
  6. FY2017First statedAnnual report

    「Research and development expenses account for a significant proportion of the expenses of our group, and we conduct research and development and capital investment ahead of time with a view to the future. However, if research and development does not produce the expected results, we may be unable to recover the research and development expenses and capital investment costs incurred in advance.」

    While conducting research and development and capital investment ahead of time, the possibility that the expected results may not be achieved and the investments may not be recovered is newly disclosed as a risk.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for PhoenixBio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Recovery of Upfront Research and Development and Capital Investment Costs | PhoenixBio Co.,Ltd. (6190) | Komori